News

VANCOUVER, BRITISH COLUMBIA, April 21, 2022- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB-FF) was the first to report cannabinoids can kill SARS-CoV-2, the virus that causes Covid-19. Pascal filed an international patent covering this work prior…

VANCOUVER, BRITISH COLUMBIA, March 16, 2022- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB-FF). Pascal has signed a term sheet dated March 16, 2022 with Shape Capital Pty Ltd. of Melbourne, Victoria (“Shape”), an investment and advisory…

VANCOUVER, BRITISH COLUMBIA, March 14, 2022- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB-FF). Pascal has arranged for the settlement of up to $474,812 in payables with the issuance of up to 5,935,151 common shares of the…

VANCOUVER, BRITISH COLUMBIA, March 1, 2022- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB-FF), is pleased to announce today the appointment of Dr. Brian Bapty as Chief Executive Officer and President, for a five year term which…

VANCOUVER, BRITISH COLUMBIA, December 14, 2021- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV: PAS) (OTC: PSCBF) (FSE: 6PB-FF) has cancelled its most recent private placement. On October 28, 2021, the Company announced a non-brokered private placement financing of up…

VANCOUVER, BRITISH COLUMBIA, November 26, 2021- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV: PAS) (OTC: PSCBF) (FSE: 6PB-FF)   On October 28, 2021, the Company announced a non-brokered private placement financing of up to 9,000,000 units (each a “Unit”)…

VANCOUVER, BRITISH COLUMBIA, October 28, 2021- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV: PAS) (OTC: PSCBF) (FSE: 6PB-FF) is pleased to announce the following actions to continue the development of the Company’s PAS-403 and PAS-393 patented molecules for development…

VANCOUVER, BRITISH COLUMBIA, September 7, 2021- Pascal Biosciences Inc. (“Pascal”) (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB-FF), announced today the appointment of Rob Gietl as Chief Executive Officer and President, and he will also have a position on the Board of Directors. Mr. Gietl…

VANCOUVER, BRITISH COLUMBIA, June 16, 2021- Pascal Biosciences Inc. (“Pascal”) (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB), announced today the appointment of Hardy Forzley as Chief Financial Officer. Mr. Forzley has used his professional expertise as a Certified Public Accountant with some 30 years…

VANCOUVER, BRITISH COLUMBIA, June 8, 2021- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV:PAS) (OTC:PSCBF), has been awarded a grant of US$343,750 from the National Cancer Institute of the US National Institutes of Health (NIH).  This two-year award will fund…